Viz HCM vs EchoNext
AI Verdict
Choose Viz HCM if…
Choose Viz HCM if your institution's primary focus is the early and accurate detection of Hypertrophic Cardiomyopathy (HCM) and streamlining the subsequent care coordination. This AI tool is specifically designed for real-time ECG analysis to identify suspected HCM cases and rapidly direct patients to appropriate specialists, significantly reducing diagnosis time for this often-underdiagnosed condition. It is particularly well-suited for hospitals and health systems aiming to improve outcomes for HCM patients through an integrated, mobile-based alert system and seamless EHR/PACS integration.
View Viz HCM →Choose EchoNext if…
Choose EchoNext if your goal is a broader screening for various hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension, using standard ECGs. This tool is ideal for diverse clinical settings, from major hospitals to community practices, seeking an affordable and non-invasive front-line screening method to identify patients who require further evaluation with an echocardiogram. It can help detect a wider range of cardiac conditions that might otherwise go undiagnosed until symptoms become severe.
View EchoNext →When choosing between Viz HCM and EchoNext, physicians should consider their primary diagnostic focus and desired workflow integration. Both are FDA-cleared AI tools that leverage ECG analysis for cardiac insights, but they differ significantly in their scope and deployment. Viz HCM is specifically designed for the real-time detection of suspected Hypertrophic Cardiomyopathy (HCM) and excels at coordinating care for this particular condition. Its strength lies in its ability to rapidly identify HCM from ECGs and then actively direct patients to appropriate specialists, streamlining the care pathway for a specific, often underdiagnosed, disease.
EchoNext, on the other hand, offers a broader diagnostic lens, analyzing standard ECGs to detect a range of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension. While Viz HCM focuses on a single condition with integrated care coordination, EchoNext provides a wider screening capability for various cardiac pathologies. The key practical difference lies in Viz HCM’s direct integration into hospital IT systems for real-time alerts and automated care team notifications, versus EchoNext’s availability through the OpenEvidence clinical decision support platform.
Therefore, a physician primarily focused on improving the timely diagnosis and coordinated management of Hypertrophic Cardiomyopathy should lean towards Viz HCM due to its specialized focus and robust care coordination features. Conversely, a physician seeking a more general screening tool to identify a broader spectrum of hidden structural heart diseases from standard ECGs would find EchoNext more suitable.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Viz HCM | EchoNext |
|---|---|---|
| Pricing | Subscription-based | Starts at $600/month |
| Deployment | Cloud-based platform, integrated into hospital IT systems (EHR, PACS). | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz HCMViz HCM is designed for seamless integration into existing clinical workflows, including EHR and PACS systems, and offers mobile-based alerts and notifications to multidisciplinary care teams. This focus on real-time, integrated, and mobile access suggests a highly usable tool that fits directly into a clinician's daily routine. EchoNext is available through the OpenEvidence platform, which is used by many physicians, but its direct integration into hospital systems and mobile-first approach for care coordination are not as explicitly detailed.
Clinical Value
EchoNextWhile both tools are FDA-cleared and leverage AI for ECG analysis, EchoNext has a broader scope, detecting multiple types of hidden structural heart disease including heart failure, valve disease, and pulmonary hypertension, with six FDA clearances. Viz HCM focuses specifically on Hypertrophic Cardiomyopathy (HCM) detection and care coordination. EchoNext has also demonstrated superior diagnostic accuracy compared to cardiologists in studies.
Pricing & Value
Viz HCMViz HCM has established CMS reimbursement for specific CPT codes, effective January 1, 2025, providing a clear pathway for financial viability for hospitals and health systems. EchoNext offers tiered subscription pricing, but lacks information on specific reimbursement codes or established payment pathways, which can be a significant barrier to adoption in healthcare.
Enterprise Readiness
Viz HCMViz HCM is deployed in 2,000 U.S. hospitals and is integrated into hospital IT systems (EHR, PACS), demonstrating a strong track record and established infrastructure for enterprise-level implementation. EchoNext is available through the OpenEvidence platform, which has broad reach, but its direct integration capabilities and widespread hospital deployment are not as extensively detailed as Viz HCM's.
Innovation
TieBoth tools represent significant innovation in cardiology AI by using standard ECGs to detect complex heart conditions that are often missed. Viz HCM was the first FDA-cleared AI algorithm for HCM detection. EchoNext is the world's first FDA-approved AI detection tool for multiple structural heart diseases from ECGs, and has demonstrated superior accuracy to cardiologists. Given their respective 'firsts' and demonstrated capabilities, neither tool definitively outweighs the other in terms of innovation.
Support & Docs
Viz HCMViz.ai provides a knowledge base with common questions, troubleshooting guides, and resources like user guides, webinars, and clinical validation publications. While EchoNext is backed by Pathway Labs and Columbia University, specific details about their ongoing support and documentation resources for end-users are not as readily available or detailed in the provided information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Viz HCM | EchoNext |
|---|---|---|
| Name | Viz HCM | EchoNext |
| Company | Viz.ai | Pathway Labs |
| Description | Viz HCM is an FDA-cleared AI tool by Viz.ai that uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM) and coordinate cardiac care, significantly reducing diagnosis time. | EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Detections | Hypertrophic Cardiomyopathy (HCM) | Hidden structural heart disease, heart failure, valve disease, pulmonary hypertension |
| Specialties | Cardiology, Emergency Medicine, Hospital Medicine | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Viz HCM and EchoNext.